Bay Street News, March, 2024

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of […]

THE WOODLANDS, Texas, March 05, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 376 homes […]

PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 […]

DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company […]

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced […]

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated […]

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in […]

HOUSTON, March 05, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”) announced today that it […]

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational […]

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) […]